In Idenix Pharmaceuticals LLC. v. Gilead Sciences Inc., [2018-1691] (October 30, 2019), the Federal Circuit affirmed that U.S. Patent No. 7,608,597 was invalid for lack of enablement, and further held that it was invalid for lack of written description as … Continue reading Synthesizing and Screening Thousands of Candidate Compounds Constitutes Undue Experimentation